Compare GSK plc (GSK) vs First Trust NASDAQ Clean Edge Green Energy Idx Fd (QCLN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs First Trust NASDAQ Clean Edge Green Energy Idx Fd — how do they compare? GSK plc trades at $46.5 (market cap $91.88B), while First Trust NASDAQ Clean Edge Green Energy Idx Fd trades at $48.35 (market cap $561.25M). The key difference: GSK plc is far larger — about 163.7× First Trust NASDAQ Clean Edge Green Energy Idx Fd's market cap, and GSK plc pays a 3.9% dividend while First Trust NASDAQ Clean Edge Green Energy Idx Fd pays none. Which is the better fit depends on your goals — on Pluang, investors hold GSK plc for 93 Days and First Trust NASDAQ Clean Edge Green Energy Idx Fd for 50 Days on average.
| GSK | QCLN | |
|---|---|---|
Market Cap | $91.88B | $561.25M |
Volume | 7,730,529 | 323,550 |
Sector | Health | Sector/Thematic |
52-Week High | $61.18 | $68.47 |
52-Week Low | $43.24 | $41.10 |
Typical Hold Time | 93 Days | 50 Days |
Enterprise Value | $111.88B | — |
Dividend Yield | 3.9% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK trades at $46.50, down 1.11% with bearish technical signals, though RSI levels suggest potential oversold conditions. Fundamentally, the company shows strong profitability with 72.73% gross margins and consistent earnings beats, while maintaining a reasonable P/E of 14.89. Recent developments include strategic oncology partnerships and a $750M cancer therapy acquisition, positioning for long-term growth despite facing an HIV patent cliff.
GSK presents a mixed investment case with strong fundamentals and pipeline growth offset by technical weakness and patent expiration risks. The company's £40B sales target and cost-saving initiatives provide upside potential, while analyst consensus leans cautious with 55% hold ratings. Key risks include execution of pipeline development and competitive pressures in core markets.
QCLN trades at $48.35, down 2.2% today, with technical indicators showing a bullish moving average signal but neutral oscillators. The ETF's performance is heavily influenced by U.S. clean energy policy and geopolitical developments, with recent news highlighting global renewable energy acceleration amid tensions. Support and resistance levels cluster around $50-$52, indicating a key price zone for near-term direction.
The outlook for QCLN hinges on political support for clean energy and rising electricity demand, offering growth potential but facing volatility from policy shifts. Risks include regulatory uncertainty and competitive pressures, while analyst sentiment remains watchful amid evolving market dynamics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About First Trust NASDAQ Clean Edge Green Energy Idx Fd
QCLN invests in U.S.-listed companies engaged in clean energy technologies. It focuses on solar power, wind, electric vehicles, and energy storage, with major holdings in firms like Tesla, ON Semiconductor, and Rivian.
Read more on QCLN →
